14 Matching Annotations
  1. Mar 2026
    1. UiO-66 的合成:本研究合成原始 UiO-66 的方法是在文献报道的经典一锅溶剂热法基础上改进而成。 35,38,45 在典型合成过程中,将 0.4728 克(2 毫摩尔)ZrCl 4 溶解于 55 毫升(711 毫摩尔,相对于 ZrCl 4 约 350 倍摩尔过量)DMF 中,超声处理 10 分钟。随后向混合物中加入 0.3372 克对苯二甲酸,再次超声处理确保完全溶解。将所得混合物转移至聚四氟乙烯反应釜中,在烘箱内从室温加热至 220°C 并维持该温度 24 小时。自然冷却至室温后静置过夜,通过离心收集白色沉淀物,用 DMF 洗涤三次、甲醇洗涤两次。最后在 60°C 真空条件下干燥过夜,得到白色粉末标记为 Zr-UiO-66。
    2. 通过结合光谱分析与理论计算,Tan 等人发现了 UiO-66 中涉及氢键羧酸与 H 2 O 物种的独特缺陷补偿机制 41

      这反映了不同竞争物种在缺陷调控中的协同作用,然而,竞争物种间的协同机制仍不明确。 K. Tan , H. Pandey , H. Wang , E. Velasco , K.-Y. Wang , H.-C. Zhou , J. Li and T. Thonhauser , Defect Termination in the UiO-66 Family of Metal–Organic Frameworks: The Role of Water and Modulator, J. Am. Chem. Soc., 2021, 143 , 6328 —6332

  2. Jan 2026
  3. Nov 2025
  4. Feb 2025
  5. Jan 2022
  6. Dec 2021
  7. Mar 2021
    1. Results for individual PALB2 variants were normalized relative to WT-PALB2 and the p.Tyr551ter (p.Y551X) truncating variant on a 1:5 scale with the fold change in GFP-positive cells for WT set at 5.0 and fold change GFP-positive cells for p.Y551X set at 1.0. The p.L24S (c.71T>C), p.L35P (c.104T>C), p.I944N (c.2831T>A), and p.L1070P (c.3209T>C) variants and all protein-truncating frame-shift and deletion variants tested were deficient in HDR activity, with normalized fold change <2.0 (approximately 40% activity) (Fig. 1a).

      AssayResult: 4.9

      AssayResultAssertion: Normal

      StandardErrorMean: 0.71

    1. Most Suspected Brugada Syndrome Variants Had (Partial) Loss of Function

      AssayResult: 5.4

      AssayResultAssertion: Abnormal

      ReplicateCount: 19

      StandardErrorMean: 1.5

      Comment: This variant had loss of function of peak current (<10% of wildtype), therefore it was considered abnormal (in vitro features consistent with Brugada Syndrome Type 1). (Personal communication: A. Glazer)